14/09/2022
I’ve been seeing some confusion around and effects so I’ve begun an ongoing series of articles on the topic.
The old 20th century model of using a single molecule drug acting on a single biochemical pathway is showing its age, especially when it comes to chronic diseases.
Limitations of patented single drugs include massive problems with drug toxicity as well as poor efficacy in the face of complex chronic illnesses.
Compared to single molecule drugs, plants can provide the therapeutic possibility of equal or greater efficacy with reduced toxicity. This is one of the great appeals of medical and for consumers..
This new approach led by advances in and cannabis research is helping lead the way forward. Over time, a slow trend in medicine can be seen moving away from the limitations of single drug applications.
By addressing multiple targets with botanicals, the combinations of different plant molecules acting on multiple biochemical pathways can provide therapeutic benefits, lower toxicity and increased bioavailability when compared to a single drug working on a single target.
Are these synergy and entourage effects real, or just clever marketing?
https://ndnr.com/pain-medicine/botanical-synergy-part-1/
